XRAY — DENTSPLY SIRONA Inc.

Summary of DENTSPLY SIRONA Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $880 million, a slight increase of 0.1% year-over-year; however, on a constant currency basis, sales declined by 6.7%.
• Adjusted EBITDA Margin: Decreased by 430 basis points, primarily due to a 560 basis point decline in gross profit attributed to lower volumes and sales mix.
• Adjusted EPS: Reported at $0.27.
• Operating Cash Flow: Improved to $40 million from $7 million in the prior year, driven by better working capital management.
• Net Debt to EBITDA Ratio: 3.3x, with $79 million of debt retired during the quarter.
• Cash and Cash Equivalents: Ended the quarter with $190 million.

2. Strategic Updates and Business Highlights

• Return to Growth Action Plan: The company is in the early stages of executing its plan aimed at driving sustained profitable growth, focusing on customer engagement, innovation, and cost optimization.
• Commercial Restructuring: Ongoing efforts in the U.S. to enhance clinical education and sales force training.
• Product Innovations: Recent launches include SmartView Detect (AI diagnostic aid), Reciproc Minima File System, and a dental-dedicated MRI.
• Distribution Partnerships: Expanded agreements with distributors, including Atlanta Dental Supply, to improve market access.
• Operational Efficiencies: A restructuring program is on track to deliver $120 million in annual savings, with early benefits seen in Q1.

3. Forward Guidance and Outlook

• 2026 Outlook: Maintaining guidance for net sales between $3.5 billion and $3.6 billion and adjusted EPS in the range of $1.40 to $1.50.
• Growth Expectations: Anticipated benefits from the return to growth initiatives are expected to materialize more significantly in the second half of 2026 and into 2027.

4. Bad News, Challenges, or Points of Concern

• Sales Decline: Constant currency sales were down 6.7%, with specific segments like EDS and OIS experiencing notable declines.
• Gross Margin Pressure: Significant contraction due to tariffs and lower sales volumes.
• Geopolitical Risks: Ongoing monitoring of external pressures, including geopolitical tensions affecting certain markets, particularly in Europe.
• Competitive Landscape: Increased competition from lower-cost entrants in the digital equipment space, particularly impacting pricing strategies.

5. Notable Q&A Insights

• Timing of Growth Benefits: Management indicated that while some benefits from the return to growth plan may be seen in the fourth quarter, more substantial improvements are expected in 2027 and 2028.
• DSO Engagement: Positive traction with Dental Service Organizations (DSOs) noted, with a focus on leveraging the broad product portfolio.
• Implant Market Strategy: Acknowledgment of challenges in implant volumes, with plans to enhance education and execution to improve performance.
• Private Label Trends: Management is aware of the shift towards private label products and is developing strategies to compete effectively.
• Capital Allocation: The elimination of the dividend has provided flexibility for debt reduction and potential share repurchases later in the year, contingent on performance improvements.

This summary encapsulates the key aspects of DENTSPLY SIRONA's Q1 2026 earnings call, highlighting financial performance, strategic initiatives, future outlook, and challenges faced by the company.